NCT05520177 - A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss | Biotech Hunter

Enrollment

350

Participants

Timeline

Start Date

December 27, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Branch Retinal Vein Occlusion

Interventions

DRUG

601 1.25mg

loading phase (6 months): 601 1.25mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses

DRUG

ranibizumab 0.5mg

loading phase (6 months): ranibizumab 0.5mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses

Trial Locations (10)

100730

RECRUITING

BeiJing Hospital, Beijing

200080

RECRUITING

ShangHai General Hospital, Shanghai

210029

RECRUITING

JiangSu Province Hospital, Nanjing

300020

RECRUITING

TianJin Eye Hospital, Tianjin

300384

RECRUITING

TianJin Medical University Eye Hospital, Tianjin

310024

RECRUITING

ZheJiang Province People's Hospital, Hangzhou

410011

RECRUITING

The Second XiangYa Hospital of Central South University, Changsha

450003

RECRUITING

HeNan Provincial Eye Hospital, Zhengzhou

510630

RECRUITING

The First Affiliated Hospital of JiNan University, Guangzhou

610000

RECRUITING

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors

lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY